Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
18.29
+0.49 (2.75%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Celldex Therapeutics Revenue
In the year 2024, Celldex Therapeutics had annual revenue of $7.02M with 1.99% growth. Celldex Therapeutics had revenue of $1.18M in the quarter ending December 31, 2024, a decrease of -71.56%.
Revenue (ttm)
$7.02M
Revenue Growth
+1.99%
P/S Ratio
167.87
Revenue / Employee
$37,742
Employees
186
Market Cap
1.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CLDX News
- 6 weeks ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - GlobeNewsWire
- 6 weeks ago - Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - GlobeNewsWire
- 7 weeks ago - Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - GlobeNewsWire
- 5 months ago - Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - GlobeNewsWire
- 5 months ago - Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha